Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Asundexian [inn]
2. 2064121-65-7
3. La585um8de
4. 4-[[(2s)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide
5. Unii-la585um8de
6. Schembl20360602
7. Gtpl11710
8. Bdbm413842
9. Glxc-25353
10. Ex-a6019
11. Us10421742, Example 235
12. Bay2433334
13. Bay 2433334
14. Bay-2433334
15. Example 235 [wo2017005725a1]
16. Hy-137431
17. Cs-0138630
18. 1(2h)-pyridineacetamide, N-(4-(aminocarbonyl)-3-fluorophenyl)-4-(5-chloro-2-(4-(trifluoromethyl)-1h-1,2,3-triazol-1-yl)phenyl)-.alpha.-ethyl-5-methoxy-2-oxo-, (.alpha.s)-
19. 1(2h)-pyridineacetamide, N-(4-(aminocarbonyl)-3-fluorophenyl)-4-(5-chloro-2-(4-(trifluoromethyl)-1h-1,2,3-triazol-1-yl)phenyl)-alpha-ethyl-5-methoxy-2-oxo-, (alphas)-
20. 4-({(2s)-2-[4-{5-chloro-2-[4-(trifluoromethyl)-1h-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2h)-yl]butanoyl}amino)-2-fluorobenzamide (enantiomer 2)
| Molecular Weight | 592.9 g/mol |
|---|---|
| Molecular Formula | C26H21ClF4N6O4 |
| XLogP3 | 3 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 8 |
| Exact Mass | 592.1248935 g/mol |
| Monoisotopic Mass | 592.1248935 g/mol |
| Topological Polar Surface Area | 132 Ų |
| Heavy Atom Count | 41 |
| Formal Charge | 0 |
| Complexity | 1080 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Asundexian manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Asundexian, including repackagers and relabelers. The FDA regulates Asundexian manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Asundexian API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Asundexian supplier is an individual or a company that provides Asundexian active pharmaceutical ingredient (API) or Asundexian finished formulations upon request. The Asundexian suppliers may include Asundexian API manufacturers, exporters, distributors and traders.
Asundexian Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Asundexian GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Asundexian GMP manufacturer or Asundexian GMP API supplier for your needs.
A Asundexian CoA (Certificate of Analysis) is a formal document that attests to Asundexian's compliance with Asundexian specifications and serves as a tool for batch-level quality control.
Asundexian CoA mostly includes findings from lab analyses of a specific batch. For each Asundexian CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Asundexian may be tested according to a variety of international standards, such as European Pharmacopoeia (Asundexian EP), Asundexian JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Asundexian USP).
LOOKING FOR A SUPPLIER?
